Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Susanne M. Picker"'
Autor:
Susanne M. Picker
Publikováno v:
Journal of Cardiovascular Pharmacology. 61:166-174
Blood platelets (PLTs) play a key role in atherothrombosis due to their ability of thrombus formation after rupture of an atherosclerotic plaque. Numerous clinical trials have established the efficacy of PLT function blockade in the prevention of acu
Autor:
Susanne M. Picker
Publikováno v:
Cardiovascular & Hematological Agents in Medicinal Chemistry. 11:49-57
Blood platelets play a key role in normal hemostasis but also in atherothrombosis due to their ability of thrombus formation at site of a ruptured atherosclerotic plaque. Platelets are also involved in vascular inflammation due to interactions with e
Publikováno v:
Transfusion. 52:510-516
BACKGROUND: Previously, we evaluated the Mirasol pathogen reduction technology (PRT) system on platelet (PLT) function before resuspension. We now evaluated this system in the presence of PLT additive solution (PAS). STUDY DESIGN AND METHODS: Double-
Publikováno v:
ISBT Science Series. 5:114-119
Background Pathogen reduction technology (PRT) has been proven to reduce the residual risk of transmission of infectious agents. Reduction of various contaminating bacteriae, viruses and parasites by few to several log steps and efficiency to prevent
Publikováno v:
Vox Sanguinis. 97:26-33
Background To examine if different pathogen-reduction technologies (PRTs) induce different degrees of platelet (PLT) storage lesion. Design Twenty-seven split triple-dose apheresis PLTs were PRT treated using ultraviolet light with either riboflavin
Publikováno v:
Transfusion. 49:1224-1232
BACKGROUND: Pathogen inactivation/reduction technology (PRT) may alter quality of stored platelet (PLT) concentrates (PCs). Therefore, PLT adhesion and aggregation should be studied before transfusion of PRT-treated PLTs. STUDY DESIGN AND METHODS: A
Publikováno v:
Transfusion and Apheresis Science. 40:79-85
Background Mirasol pathogen reduction technology (PRT) treatment uses riboflavin (vitamin B 2 ) in combination with ultraviolet light (UV) to inactivate pathogens in platelet concentrates (PCs). This treatment has been reported to increase glycolytic
Autor:
Birgit S. Gathof, Susanne M. Picker, Paul M. Schneider, Arnulf H. Hoelscher, Daniel Vallböhmer, Elfriede Bollschweiler, Frederike C. Ling, Daniel R. Schmidt
Publikováno v:
Journal of Gastrointestinal Surgery. 13:581-586
Perioperative transfusion of allogeneic blood has been hypothesized to have an immunomodulatory effect and influence survival in several cancer types. This study evaluates the association between receipt of leucocyte-depleted and non-depleted allogen
Publikováno v:
Transfusion Medicine and Hemotherapy. 36:114-120
BACKGROUND: Soluble mediators in platelet concentrates (PCs) released from contaminating white blood cells (WBCs) and platelets (PLTs) themselves are supposed to promote allergic and non-hemolytic febrile transfusion reactions in the recipient. Patho
Publikováno v:
Transfusion. 48:1685-1692
Background The aim of this study was to examine the effects of a new riboflavin-based pathogen reduction technology (PRT), the Mirasol PRT process (Navigant Biotechnologies) on platelet (PLT) storage lesion development. Study design and methods A thr